Dr. O'Meara is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
21823 30th Dr Se
Bothell, WA 98021Phone+1 425-527-4000
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2008 - 2011- University of WashingtonResidency, Internal Medicine, 2005 - 2008
University of Arizona College of MedicineClass of 2005
Certifications & Licensure
WA State Medical License 2009 - 2027- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2016 May 01
- A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Publications & Presentations
PubMed
- 47 citationsA phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi
Blood. 2018-09-13 - 27 citationsImmunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.Denise L. Cecil, Meredith Slota, Megan M. O'Meara, Benjamin Curtis, Ekram Gad
Clinical Cancer Research. 2017-07-01 - 37 citationsBrentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacyAjay K. Gopal, Nancy L. Bartlett, Andres Forero-Torres, Anas Younes, Robert T. Chen
Leukemia & Lymphoma. 2014-02-24
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
